High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era

Leukemia and Lymphoma

Volumn 53, Issue 5, 2012, Pages 830-835

  Ban Hoefen, Makiko ^a   Kelly, Jennifer L ^a   Bernstein, Steven H ^a   Liesveld, Jane ^a   Constine, Louis ^a   Becker, Michael ^a   Milner, Laurie ^a   Phillips, Gordon ^a   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

HD ASCT; rituximab; transformed NHL; transplant

Indexed keywords

ANTHRACYCLINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RITUXIMAB;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CONDITIONING; DRUG MEGADOSE; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WHOLE BODY RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84859934376     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.631637     Document Type: Article

References (33)

1. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005;23:8447-8452.
2. Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 2005;23:5019-5026. (Pubitemid 46224008)
3. Al-Tourah AJ, Gill KK, Chhanabhai M, et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 2008;26:5165-5169.
4. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587-1594. (Pubitemid 27167397)
5. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diff use large B-cell lymphoma. J Clin Oncol 2007;25:2426-2433. (Pubitemid 47007616)
6. Bernstein SH, Burack WR. Th e incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009:532-541.
7. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002;346:235-242. (Pubitemid 34438862)
8. Habermann TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24: 3121-3127. (Pubitemid 46638950)
9. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) signifi cantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732. (Pubitemid 41742196)
10. Al-Tourah AJ, Savage KJ, Gill KK, et al. Addition of rituximab to CHOP chemotherapy signifi cantly improves survival of patients with transformed lymphoma. Blood 2007;110(Suppl. 1): Abstract 790.
11. Phillips GL, Bernstein SH, Liesveld JL, et al. A phase I trial: dose escalation of melphalan in the " BEAM " regimen using amifostine cytoprotection. Biol Blood Marrow Transplant 2011;17:1033-1042.
12. NCCN Clinical Practice Guidelines in Oncology, version 2.2011. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
13. Chen CI, Crump M, Tsang R, et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001;113:202-208. (Pubitemid 32423324)
14. Foran JM, Apostolidis J, Papamichael D, et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998;9:865-869. (Pubitemid 28440445)
15. Friedberg JW, Neuberg D, Gribben JG, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999;5:262-268.
16. Ramadan KM, Connors JM, Al-Tourah A, et al. Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma. Blood 2008;112(Suppl. 1): Abstract 4459.
17. Sabloff M, Atkins HL, Bence-Bruckler I, et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007;13:956-964. (Pubitemid 47055389)
18. Williams CD, Harrison CN, Lister TA, et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001;19:727-735. (Pubitemid 32119087)
19. Friedberg JW. Potential long-term toxicities should infl uence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematologica 2006;91:1453-1455. (Pubitemid 44736110)
20. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3128-3135. (Pubitemid 29470642)
21. Smith SD, Bolwell BJ, Advani AS, et al. High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diff use large B-cell lymphoma. Leuk Lymphoma 2009;50:1625-1631.
22. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Briere J, Moskowitz CH, Schmitz N. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28(27):4184-90.
23. Tan D, Rosenberg SA, Levy R, et al. Survival in follicular lymphoma: the Stanford experience, 1960-2003. Blood 2007;110(Suppl. 1): Abstract 3428.
24. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005:329-334.
25. Eide MB, Lauritzsen GF, Kvalheim G, et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011;152:600-610.
26. Schaefer-Cutillo J, Friedberg JW, Fisher RI. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park) 2007;21:203 - 212; discussion 214, 217, 221. (Pubitemid 46331734)
27. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I] tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults or 60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396-1402. (Pubitemid 46706888)
28. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemoradioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002;99:3158-3162. (Pubitemid 34525293)
29. Clavert A, Le Gouill S, Brissot E, et al. Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2010;51: 1502-1508.
30. Rezvani AR, Storer B, Maris M, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. J Clin Oncol 2008;26:211-217.
31. Ritchie DS. Is allogeneic stem cell transplantation for transformed follicular lymphoma anti-lymphoma stem cell therapy? Leuk Lymphoma 2008;49:1852-1853.
32. Ramadan KM, Connors JM, Al-Tourah AJ, et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008;42:601-608.
33. Villa D, Savage K, Crump M, et al. Autologous and allogeneic stem cell transplantation for transformed indolent non-hodgkin lymphoma: a report of the Candian Blood and Marrow Transplant Group (CBMTG). Ann Oncol 2011;22(Suppl. 5):1-144. [Abstract].